Epilepsy Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Takeda Pharmaceutical, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer, Inc., Sanofi SA,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Epilepsy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Epilepsy Pipeline Report: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years.
• Epilepsy companies working in the treatment market are Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment
• Emerging Epilepsy therapies in the different phases of clinical trials are- RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.
• In January 2024, US-based biotech company Longboard Pharmaceuticals has reported promising topline results from the Phase Ib/IIa study of LP352 (bexicaserin) for treating developmental and epileptic encephalopathies (DEEs). The randomized, double-blind, placebo-controlled PACIFIC trial (NCT05364021) included 52 patients with DEEs to assess the safety and efficacy of LP352 at doses of 6mg, 9mg, and 12mg three times daily compared to a placebo. The trial's primary endpoint was the median change in countable motor seizure frequency, with LP352-treated patients experiencing a 53.3% reduction versus a 20.8% reduction in the placebo group.
• In January 2023, Amzell has commenced a randomized, open-label study aimed at assessing the superiority of AMZ002 in treating infantile spasms, a rare form of epilepsy. The primary objective of this study is to compare the efficacy and safety of AMZ002 with Vigabatrin in individuals newly diagnosed with infantile spasms (IS).
• In March 2022, Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Vigabatrin. This anti-epileptic medication is offered in the form of an oral solution USP (500 mg).

Epilepsy Overview
A chronic neurological illness called epilepsy is typified by recurrent, frequent seizures that cause atypical behavior. Because the causes, severity, and types of seizures vary, it may be classified as a spectrum disorder. The disorder known as epilepsy is characterized by abnormal or excessive electrical discharges from brain cells that impair brain function.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:
• RLS103: Receptor Life Sciences
• CT-010: Cerebral Therapeutics
• EQU 001: Equilibre Biopharmaceuticals
• Darigabat: Cerevel Therapeutics
• Kv7 Program: Elium Therapeutics
• CG 01: CombiGen
• OV329: Ovid Therapeutics
• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
• SKL24741: SK Biopharmaceuticals
• ENX-101: Engrail Therapeutics
• AMZ002: Amzell
• XEN496: Xenon Pharmaceuticals Inc.

Epilepsy Route of Administration
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Epilepsy Molecule Type
Epilepsy Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Epilepsy Pipeline Therapeutics Assessment
• Epilepsy Assessment by Product Type
• Epilepsy By Stage and Product Type
• Epilepsy Assessment by Route of Administration
• Epilepsy By Stage and Route of Administration
• Epilepsy Assessment by Molecule Type
• Epilepsy by Stage and Molecule Type
DelveInsight's Epilepsy Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Epilepsy Therapeutics Market include:
Key companies developing therapies for Epilepsy are - Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Sunovion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical, GW Pharmaceuticals plc, H. Lundbeck A/S, Alkem Labs., Eisai Co., and others.

Epilepsy Pipeline Analysis:
The Epilepsy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Epilepsy drugs and therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Epilepsy Pipeline Market Drivers
• Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

Epilepsy Pipeline Market Barriers
• However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

Scope of Epilepsy Pipeline Drug Insight
• Coverage: Global
• Key Epilepsy Companies: Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
• Key Epilepsy Therapies: RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Epilepsy Report Introduction
2. Epilepsy Executive Summary
3. Epilepsy Overview
4. Epilepsy- Analytical Perspective In-depth Commercial Assessment
5. Epilepsy Pipeline Therapeutics
6. Epilepsy Late Stage Products (Phase II/III)
7. Epilepsy Mid Stage Products (Phase II)
8. Epilepsy Early Stage Products (Phase I)
9. Epilepsy Preclinical Stage Products
10. Epilepsy Therapeutics Assessment
11. Epilepsy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Epilepsy Key Companies
14. Epilepsy Key Products
15. Epilepsy Unmet Needs
16 . Epilepsy Market Drivers and Barriers
17. Epilepsy Future Perspectives and Conclusion
18. Epilepsy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Epilepsy Market https://www.delveinsight.com/report-store/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Epilepsy Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.